Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study. J of Skin [Internet]. 2023 Mar. 13 [cited 2026 May 25];7(2):s153. Available from: https://skin.dermsquared.com/skin/article/view/1988